J INTERN MED:PCSK9与感染性休克患者死亡率相关

2020-07-20 MedSci原创 MedSci原创

在对ALBIOS试验的子分析中,研究人员发现感染性休克患者血浆PCSK9水平较低,死亡率更高。有必要进行进一步的研究,以更好地评估PCSK9在败血症中的病理生理学作用。

前蛋白转化酶枯草杆菌蛋白酶9(PCSK9)是一种主要能调节肝细胞中低密度脂蛋白受体再摄取的酶。尚不清楚PCSK9是否可以同时引发炎症。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员旨在调查严重败血症或感染性休克患者PCSK9循环水平与死亡率之间的潜在关联。

研究人员对958名严重败血症或感染性休克患者第1天、第2天和第7天测量了血浆PCSK9水平,这些患者先前已参加了意大利白蛋白结局败血症(ALBIOS)试验。研究人员用排名后的Spearman系数评估了PCSK9和五环素3(PTX3)(一种疾病严重程度的生物标记)水平之间的相关性,并使用Cox比例风险模型评估第1天PCSK9水平与28天和90天死亡率之间的关联。

第1天的血浆PCSK9水平中位数为278 [182-452] ng/mL。在三个时间点,PCSK9与PTX3呈正相关,PCSK9处于第一个四分位数的感染性休克患者具有较高的PTX3水平。在PCSK9各个四分位数之间的严重败血症患者中观察到相似的死亡率。与其他四分位数相比,在第1天PCSK9水平处于第一个四分位数之内的感染性休克患者具有最高的28天和90天死亡率。

由此可见,在对ALBIOS试验的子分析中,研究人员发现感染性休克患者血浆PCSK9水平较低,死亡率更高。有必要进行进一步的研究,以更好地评估PCSK9在败血症中的病理生理学作用。

原始出处:

Alessandra Vecchié.et al.PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study.J INTERN MED. 2020.https://doi.org/10.1111/joim.13150

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-25 FukaiBao
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2021-03-02 Tamikia
  5. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-08-11 14631baam13暂无昵称

    👌

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-21 12543f43m99暂无昵称

    阅读

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1777295, encodeId=0b081e7729521, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sat Jul 25 14:24:05 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655495, encodeId=8b1a165549526, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Jun 24 01:24:05 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983676, encodeId=220819836e6d1, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 25 16:24:05 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685640, encodeId=b9b61685640e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 02 02:24:05 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807467, encodeId=068780e4673b, content=👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Tue Aug 11 13:16:04 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610576, encodeId=5b3116105e607, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 22 05:24:05 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803736, encodeId=5c44803e363b, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Jul 21 20:44:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803485, encodeId=f9b38034859f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/HI2dSia2Xe48PYK0xfLLOyIPvSYobPrdl8ZtRcjBN6XWrx207onjgRFQjaTZ1QZbUPGDHBicQvFZOELxdXl0nfXg/132, createdBy=275d5266319, createdName=hugeyang, createdTime=Mon Jul 20 14:43:48 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 hugeyang

    0

相关资讯

BMJ:充分的有氧及肌肉强化活动可降低死亡风险

在《2018年美国体育活动指南》推荐的水平上进行业余有氧运动和肌肉强化活动成年人的全因和特定原因死亡风险大大降低

Crit Care:急性低氧血症性呼吸衰竭和急性呼吸窘迫综合征患者的死亡原因和特征

急性低氧血症性呼吸衰竭(AHRF)和急性呼吸窘迫综合征(ARDS)与高院内死亡率相关。但是,在1990年代的ARDS患者队列中,患者死于败血症或多器官功能衰竭而不是难治性低氧血症更为常见。在过去的25

Eur Respir J:肺间质异常与癌症诊断和死亡率的关系

间质性肺异常的人罹患肺癌和肺癌死亡的风险增加,而其他癌症则没有。这意味着从肺纤维化的早期就存在肺纤维化和肿瘤性肺疾病之间的关联,并提示间质性肺异常是肺癌筛查工作中的危险因素。

AP&T:体弱与炎症性肠病患者的死亡率独立相关

患有炎症性肠病(IBD)的老年人的患病率正在上升。虚弱是许多慢性病状态下预后的重要预测指标。在IBD中,体质虚弱的影响尚未得到很好的描述。本项研究旨在探究IBD患者的体质和死亡率之间的关联。

Crit Care:血浆胱抑素C升高与急性呼吸窘迫综合征患者死亡率有关

胱抑素C是慢性肾脏疾病中肾小球滤过率的有效标记。在重症患者的异质人群中,较高的血浆中胱抑素C浓度与较差的临床结局相关,在确定重症患者的肾脏损伤方面可能优于肌酐。近日,危重病医学领域权威杂志Critic

Crit Care:COVID-19住院患者急性并发症和死亡率

基于非均质性和偏见风险,以及非常低质量的证据,危重患者的死亡率很高。尽管只有三分之一的研究报告了临床相关结局,但其发生率很高。